Hudson AM - Search Results

1

Truncation- and motif-based pan-cancer analysis reveals tumor-suppressing kinases.

Hudson AM, Stephenson NL, Li C, Trotter E, Fletcher AJ, Katona G, Bieniasz-Krzywiec P, Howell M, Wirth C, Furney S, Miller CJ, Brognard J. Hudson AM, et al. Sci Signal. 2018 Apr 17;11(526):eaan6776. doi: 10.1126/scisignal.aan6776. Sci Signal. 2018. PMID: 29666306 Free PMC article.

2

Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors.

Marusiak AA, Edwards ZC, Hugo W, Trotter EW, Girotti MR, Stephenson NL, Kong X, Gartside MG, Fawdar S, Hudson A, Breitwieser W, Hayward NK, Marais R, Lo RS, Brognard J. Marusiak AA, et al. Nat Commun. 2014 May 22;5:3901. doi: 10.1038/ncomms4901. Nat Commun. 2014. PMID: 24849047 Free PMC article.

3

Discrepancies in cancer genomic sequencing highlight opportunities for driver mutation discovery.

Hudson AM, Yates T, Li Y, Trotter EW, Fawdar S, Chapman P, Lorigan P, Biankin A, Miller CJ, Brognard J. Hudson AM, et al. Cancer Res. 2014 Nov 15;74(22):6390-6396. doi: 10.1158/0008-5472.CAN-14-1020. Epub 2014 Sep 25. Cancer Res. 2014. PMID: 25256751 Free PMC article.

4

Cancer-associated protein kinase C mutations reveal kinase's role as tumor suppressor.

Antal CE, Hudson AM, Kang E, Zanca C, Wirth C, Stephenson NL, Trotter EW, Gallegos LL, Miller CJ, Furnari FB, Hunter T, Brognard J, Newton AC. Antal CE, et al. Among authors: hudson am. Cell. 2015 Jan 29;160(3):489-502. doi: 10.1016/j.cell.2015.01.001. Epub 2015 Jan 22. Cell. 2015. PMID: 25619690 Free PMC article.

5

Using large-scale genomics data to identify driver mutations in lung cancer: methods and challenges.

Hudson AM, Wirth C, Stephenson NL, Fawdar S, Brognard J, Miller CJ. Hudson AM, et al. Pharmacogenomics. 2015;16(10):1149-60. doi: 10.2217/pgs.15.60. Epub 2015 Jul 31. Pharmacogenomics. 2015. PMID: 26230733 Free article. Review.

6

Somatically mutated ABL1 is an actionable and essential NSCLC survival gene.

Testoni E, Stephenson NL, Torres-Ayuso P, Marusiak AA, Trotter EW, Hudson A, Hodgkinson CL, Morrow CJ, Dive C, Brognard J. Testoni E, et al. EMBO Mol Med. 2016 Feb 1;8(2):105-16. doi: 10.15252/emmm.201505456. EMBO Mol Med. 2016. PMID: 26758680 Free PMC article.

7

Palliative Lung Radiotherapy: Higher Dose Leads to Improved Survival?

Lewis TS, Kennedy JA, Price GJ, Mee T, Woolf DK, Bayman NA, Chan C, Coote JH, Faivre-Finn C, Harris MA, Hudson AM, Pemberton LS, Salem A, Sheikh HY, Mistry HB, Cobben DCP. Lewis TS, et al. Among authors: hudson am. Clin Oncol (R Coll Radiol). 2020 Oct;32(10):674-684. doi: 10.1016/j.clon.2020.05.003. Epub 2020 Jun 26. Clin Oncol (R Coll Radiol). 2020. PMID: 32600918 Free PMC article. Clinical Trial.

8

Is heterogeneity in stage 3 non-small cell lung cancer obscuring the potential benefits of dose-escalated concurrent chemo-radiotherapy in clinical trials?

Hudson A, Chan C, Woolf D, McWilliam A, Hiley C, O'Connor J, Bayman N, Blackhall F, Faivre-Finn C. Hudson A, et al. Lung Cancer. 2018 Apr;118:139-147. doi: 10.1016/j.lungcan.2018.02.006. Epub 2018 Feb 14. Lung Cancer. 2018. PMID: 29571993 Review.

9

What Three Wise Men have to say about diagnosis.

Mani N, Slevin N, Hudson A. Mani N, et al. BMJ. 2011 Dec 20;343:d7769. doi: 10.1136/bmj.d7769. BMJ. 2011. PMID: 22187188 No abstract available.

10

[No title available]

[No authors listed] [No authors listed] PMID: 37785368

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

57 results

Search Page

Filters